189 related articles for article (PubMed ID: 37349576)
21. Combined effect of cabozantinib and gefitinib in crizotinib-resistant lung tumors harboring ROS1 fusions.
Kato Y; Ninomiya K; Ohashi K; Tomida S; Makimoto G; Watanabe H; Kudo K; Matsumoto S; Umemura S; Goto K; Ichihara E; Ninomiya T; Kubo T; Sato A; Hotta K; Tabata M; Toyooka S; Maeda Y; Kiura K
Cancer Sci; 2018 Oct; 109(10):3149-3158. PubMed ID: 30053332
[TBL] [Abstract][Full Text] [Related]
22. Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor-Sensitive and -Resistant Chronic Myeloid Leukemia.
Ben-Batalla I; Erdmann R; Jørgensen H; Mitchell R; Ernst T; von Amsberg G; Schafhausen P; Velthaus JL; Rankin S; Clark RE; Koschmieder S; Schultze A; Mitra S; Vandenberghe P; Brümmendorf TH; Carmeliet P; Hochhaus A; Pantel K; Bokemeyer C; Helgason GV; Holyoake TL; Loges S
Clin Cancer Res; 2017 May; 23(9):2289-2300. PubMed ID: 27856601
[No Abstract] [Full Text] [Related]
23. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer.
Zhang Z; Lee JC; Lin L; Olivas V; Au V; LaFramboise T; Abdel-Rahman M; Wang X; Levine AD; Rho JK; Choi YJ; Choi CM; Kim SW; Jang SJ; Park YS; Kim WS; Lee DH; Lee JS; Miller VA; Arcila M; Ladanyi M; Moonsamy P; Sawyers C; Boggon TJ; Ma PC; Costa C; Taron M; Rosell R; Halmos B; Bivona TG
Nat Genet; 2012 Jul; 44(8):852-60. PubMed ID: 22751098
[TBL] [Abstract][Full Text] [Related]
24. The receptor tyrosine kinase Axl in cancer: biological functions and therapeutic implications.
Paccez JD; Vogelsang M; Parker MI; Zerbini LF
Int J Cancer; 2014 Mar; 134(5):1024-33. PubMed ID: 23649974
[TBL] [Abstract][Full Text] [Related]
25. AXL and MET receptor tyrosine kinases are essential for lung cancer metastasis.
Choi YJ; Kim JH; Rho JK; Kim JS; Choi CM; Kim WS; Son J; Lee JC
Oncol Rep; 2017 Apr; 37(4):2201-2208. PubMed ID: 28260071
[TBL] [Abstract][Full Text] [Related]
26. Tumor tissue and plasma levels of AXL and GAS6 before and after tyrosine kinase inhibitor treatment in EGFR-mutated non-small cell lung cancer.
Nonagase Y; Takeda M; Azuma K; Hayashi H; Haratani K; Tanaka K; Yonesaka K; Ishii H; Hoshino T; Nakagawa K
Thorac Cancer; 2019 Oct; 10(10):1928-1935. PubMed ID: 31419057
[TBL] [Abstract][Full Text] [Related]
27. Integrated analysis of multiple receptor tyrosine kinases identifies Axl as a therapeutic target and mediator of resistance to sorafenib in hepatocellular carcinoma.
Pinato DJ; Brown MW; Trousil S; Aboagye EO; Beaumont J; Zhang H; Coley HM; Mauri FA; Sharma R
Br J Cancer; 2019 Mar; 120(5):512-521. PubMed ID: 30765873
[TBL] [Abstract][Full Text] [Related]
28. MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation.
Rho JK; Choi YJ; Kim SY; Kim TW; Choi EK; Yoon SJ; Park BM; Park E; Bae JH; Choi CM; Lee JC
Cancer Res; 2014 Jan; 74(1):253-62. PubMed ID: 24165158
[TBL] [Abstract][Full Text] [Related]
29. The tumour suppressor OPCML promotes AXL inactivation by the phosphatase PTPRG in ovarian cancer.
Antony J; Zanini E; Kelly Z; Tan TZ; Karali E; Alomary M; Jung Y; Nixon K; Cunnea P; Fotopoulou C; Paterson A; Roy-Nawathe S; Mills GB; Huang RY; Thiery JP; Gabra H; Recchi C
EMBO Rep; 2018 Aug; 19(8):. PubMed ID: 29907679
[TBL] [Abstract][Full Text] [Related]
30. YAP-Dependent AXL Overexpression Mediates Resistance to EGFR Inhibitors in NSCLC.
Ghiso E; Migliore C; Ciciriello V; Morando E; Petrelli A; Corso S; De Luca E; Gatti G; Volante M; Giordano S
Neoplasia; 2017 Dec; 19(12):1012-1021. PubMed ID: 29136529
[TBL] [Abstract][Full Text] [Related]
31. AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells.
Taniguchi H; Yamada T; Wang R; Tanimura K; Adachi Y; Nishiyama A; Tanimoto A; Takeuchi S; Araujo LH; Boroni M; Yoshimura A; Shiotsu S; Matsumoto I; Watanabe S; Kikuchi T; Miura S; Tanaka H; Kitazaki T; Yamaguchi H; Mukae H; Uchino J; Uehara H; Takayama K; Yano S
Nat Commun; 2019 Jan; 10(1):259. PubMed ID: 30651547
[TBL] [Abstract][Full Text] [Related]
32. Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in
Namba K; Shien K; Takahashi Y; Torigoe H; Sato H; Yoshioka T; Takeda T; Kurihara E; Ogoshi Y; Yamamoto H; Soh J; Tomida S; Toyooka S
Mol Cancer Res; 2019 Feb; 17(2):499-507. PubMed ID: 30463991
[TBL] [Abstract][Full Text] [Related]
33. AXL Knock-Out in SNU475 Hepatocellular Carcinoma Cells Provides Evidence for Lethal Effect Associated with G2 Arrest and Polyploidization.
Batur T; Argundogan A; Keles U; Mutlu Z; Alotaibi H; Senturk S; Ozturk M
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948046
[TBL] [Abstract][Full Text] [Related]
34. Axl-altered microRNAs regulate tumorigenicity and gefitinib resistance in lung cancer.
Wang Y; Xia H; Zhuang Z; Miao L; Chen X; Cai H
Cell Death Dis; 2014 May; 5(5):e1227. PubMed ID: 24832599
[TBL] [Abstract][Full Text] [Related]
35. A Functional Role of GAS6/TAM in Nonalcoholic Steatohepatitis Progression Implicates AXL as Therapeutic Target.
Tutusaus A; de Gregorio E; Cucarull B; Cristóbal H; Aresté C; Graupera I; Coll M; Colell A; Gausdal G; Lorens JB; García de Frutos P; Morales A; Marí M
Cell Mol Gastroenterol Hepatol; 2020; 9(3):349-368. PubMed ID: 31689560
[TBL] [Abstract][Full Text] [Related]
36. Acquired resistance to EGFR tyrosine kinase inhibitors is mediated by the reactivation of STC2/JUN/AXL signaling in lung cancer.
Liu YN; Tsai MF; Wu SG; Chang TH; Tsai TH; Gow CH; Chang YL; Shih JY
Int J Cancer; 2019 Sep; 145(6):1609-1624. PubMed ID: 31162839
[TBL] [Abstract][Full Text] [Related]
37. Gas6/Axl Axis Contributes to Chemoresistance and Metastasis in Breast Cancer through Akt/GSK-3β/β-catenin Signaling.
Wang C; Jin H; Wang N; Fan S; Wang Y; Zhang Y; Wei L; Tao X; Gu D; Zhao F; Fang J; Yao M; Qin W
Theranostics; 2016; 6(8):1205-19. PubMed ID: 27279912
[TBL] [Abstract][Full Text] [Related]
38. ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in
Okura N; Nishioka N; Yamada T; Taniguchi H; Tanimura K; Katayama Y; Yoshimura A; Watanabe S; Kikuchi T; Shiotsu S; Kitazaki T; Nishiyama A; Iwasaku M; Kaneko Y; Uchino J; Uehara H; Horinaka M; Sakai T; Tanaka K; Kozaki R; Yano S; Takayama K
Clin Cancer Res; 2020 May; 26(9):2244-2256. PubMed ID: 31953310
[TBL] [Abstract][Full Text] [Related]
39. Targeting AXL and the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Melanoma.
Flem-Karlsen K; McFadden E; Omar N; Haugen MH; Øy GF; Ryder T; Gullestad HP; Hermann R; Mælandsmo GM; Flørenes VA
Mol Cancer Ther; 2020 Mar; 19(3):895-905. PubMed ID: 31871265
[TBL] [Abstract][Full Text] [Related]
40. The miR‑625‑3p/AXL axis induces non‑T790M acquired resistance to EGFR‑TKI via activation of the TGF‑β/Smad pathway and EMT in EGFR‑mutant non‑small cell lung cancer.
Du W; Sun L; Liu T; Zhu J; Zeng Y; Zhang Y; Wang X; Liu Z; Huang JA
Oncol Rep; 2020 Jul; 44(1):185-195. PubMed ID: 32319651
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]